Zacks.com on MSN20h
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...
Pulmonaryhypertensionnews.com22h
Early Winrevair trial end to allow all patients to start active treatment
Merck is ending a Phase 3 trial of Winrevair early so all PAH patients in HYPERION can start active treatment with the drug ...
Zacks.com on MSN23h
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More
Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...